LIDOCAINE HYDROCHLO

Lidocaine Hydrochloride and Epinephrine, USP, is a parenteral injectable pharmaceutical product containing a 2 percent concentration of lidocaine hydrochloride and a 1:50,000 dilution of epinephrine bitartrate, supplied in 1.7 mL single-dose cartridges. Each unit of issue consists of a package of 50 cartridges, organized in five blisters of ten per cardboard box. The product must be stored at controlled room temperature below 25°C (77°F), protected from light, and must not be frozen. It is regulated by the FDA and has a non-extendable shelf life of 18 months as a Type I (Code K) item. Packaging and marking must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and must ensure the product is sealed, protected from damage, and shipped in suitable commercial containers to guarantee safe delivery. Technical and quality requirements referenced in the document are governed by the DLA Master List of Technical and Quality Requirements, with revisions controlled based on solicitation or award date depending on acquisition type. This procurement is issued under Solicitation Number SPE2DP-26-T-4333 by the Department of Defense’s Medical Supply Chain Pharm FSA. One pack (PG) of 50 cartridges is required, with a delivery requirement of five days after award, delivered FOB destination to JBER, Alaska. The NSN is 6505-01-576-2767 and the purchase request number is 7017631646. The product must be supplied by an approved manufacturer with part number NDC66312-0181-16 or equivalent, and shipment must adhere to all DLA packaging standards, including commercial packaging for medical items and specific marking requirements. No quantity variance is permitted, and inspection and acceptance occur at the destination. The required delivery date is July 29, 2026, and the response deadline for the solicitation is August 3, 2026. The contracting officer must submit a referral in EBS for confirmation, including manufacturer and bidder details. Transportation and delivery logistics are governed by DLA procedural notes C19 and C20, with the point of contact for inquiries being Timothy McCauley.